KAS
SGMT icon

Kestra Advisory Services’s Sagimet Biosciences SGMT Stock Holding History

Kestra Advisory Services’s Portfolio SGMT Stock Details SGMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$347K Buy
66,414
+400
+0.6% +$2.23K ﹤0.01% 2503
2025
Q4 		$391K Buy
+66,014
New +$474K ﹤0.01% 2331

Other funds holding SGMT

VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Kestra Advisory Services's SGMT Position: Q1 2026 in Review

Kestra Advisory Services increased its Sagimet Biosciences (SGMT) stake by 0.61% in Q1 2026, buying an estimated $2.23K and bringing the position to 66,414 shares worth $347K. The position accounts for ﹤0.01% of the portfolio, ranked #2503.

Kestra Advisory Services first reported a position in SGMT in Q4 2025 and has held it in 2 quarters since. The position peaked at $391K in Q4 2025. 88 funds tracked by Wall St. Rank hold SGMT as of Q1 2026.

  • Kestra Advisory Services held 66,414 shares of Sagimet Biosciences worth $347K as of Q1 2026.
  • Kestra Advisory Services bought 400 Sagimet Biosciences shares in Q1 2026, an estimated $2.23K.
  • Sagimet Biosciences made up ﹤0.01% of Kestra Advisory Services's portfolio in Q1 2026, its #2503 holding.
  • Kestra Advisory Services first reported a position in Sagimet Biosciences in Q4 2025 and has held it in 2 quarters since.
  • Kestra Advisory Services's Sagimet Biosciences position peaked at $391K in Q4 2025.
  • 88 funds tracked by Wall St. Rank held Sagimet Biosciences as of Q1 2026.

Based on Kestra Advisory Services's 13F filing for Q1 2026, filed 30 Apr 2026.